A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers
Status:
TERMINATED
Trial end date:
2023-10-23
Target enrollment:
Participant gender:
Summary
This clinical trial will include two parts, i.e., Part A and Part B.
The goal of the Part A is to define the shortest safe and tolerable duration of an intravenous injection of Fosnetupitant 235 mg solution among 4 durations tested in male and female adult healthy volunteers. In study part A, researchers will compare Fosnetupitant 235 mg solution to Akynzeo solution.
The duration determined in Part A will be investigated in study Part B.
The Part B of the study was not performed.
Phase:
PHASE1
Details
Lead Sponsor:
Helsinn Healthcare SA
Treatments:
netupitant, palosentron drug combination Solutions